OncoMatch/Clinical Trials/NCT06977074
PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC
Is NCT06977074 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including PD-1 inhibitor and Platinum Doublet for non-small cell lung cancer (nsclc).
Treatment: PD-1 inhibitor · Platinum Doublet — The goal of this clinical trial is to evaluate the clinical value of ctDNA testing in guiding the optimization of immunochemotherapy cycles during induction treatment for resectable patients with NSCLC. The main questions it aims to answer are: * Does ctDNA clearance indicate pathological complete response? * Are additional cycles of immunochemotherapy necessary for patients who have ctDNA clearance after initial cycles of treatment? Researchers will use ctDNA dynamics to guide the cycles of induction treatment to see if some patients can avoid excessive cycles of treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Disease stage
Required: Stage IIA, IIB, IIIA, IIIB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Prior anti-PD-1/PD-L1/CTLA-4 therapy
Cannot have received: anti-PD-L1 therapy
Prior anti-PD-1/PD-L1/CTLA-4 therapy
Cannot have received: anti-CTLA-4 therapy
Prior anti-PD-1/PD-L1/CTLA-4 therapy
Lab requirements
Blood counts
neutrophils ≥1.5×10⁹/l, platelets ≥100×10⁹/l, hb >9 g/dl
Kidney function
cr ≤1.5×uln
Liver function
ast/alt ≤3×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify